Globe Newswire (Mon, 20-May 7:11 PM ET)
Globe Newswire (Mon, 20-May 3:39 PM ET)
TipRanks (Mon, 20-May 5:50 AM ET)
Globe Newswire (Mon, 20-May 4:00 AM ET)
TipRanks (Mon, 20-May 2:20 AM ET)
Globe Newswire (Sat, 18-May 10:00 AM ET)
Globe Newswire (Fri, 17-May 1:05 PM ET)
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRx
PRNewswire (Fri, 17-May 11:55 AM ET)
Globe Newswire (Thu, 16-May 10:00 PM ET)
Business Wire (Thu, 16-May 5:32 PM ET)
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Goodrx Holdings - Class A trades on the NASDAQ stock market under the symbol GDRX.
As of May 20, 2024, GDRX stock price declined to $7.13 with 1,643,814 million shares trading.
GDRX has a beta of 1.93, meaning it tends to be more sensitive to market movements. GDRX has a correlation of 0.10 to the broad based SPY ETF.
GDRX has a market cap of $2.67 billion. This is considered a Mid Cap stock.
Last quarter Goodrx Holdings - Class A reported $198 million in Revenue and $.08 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.01.
In the last 3 years, GDRX stock traded as high as $48.05 and as low as $3.82.
The top ETF exchange traded funds that GDRX belongs to (by Net Assets): VTI, VB, VXF, VBK, SCHA.
GDRX has outperformed the market in the last year with a return of +35.4%, while the SPY ETF gained +29.3%. In the last 3 month period, GDRX beat the market returning +10.5%, while SPY returned +6.4%. However, in the most recent 2 weeks GDRX has underperformed the stock market by returning +0.4%, while SPY returned +3.7%.
GDRX support price is $7.19 and resistance is $7.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDRX stock will trade within this expected range on the day.